Study of Hepatitis C Virus Outcomes After Treatment in Patients with Bleeding Disorders

Clinical Trial Title

Hepatitis C virus (HCV) outcomes after treatment with direct acting agents (DAA) in patients with bleeding disorders.

Contact Information

Lisa Boggio, MD

Clinical Trial Protocol Description:

Blood collection for HCV:

  • Six months after Baseline Visit
  • 1 year after Baseline
  • 18 Months after Baseline
  • 2 Years after Baseline

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are a male or female with hemophilia or other bleeding disorder.
  • Are 25 years of age or older.
  • Have had exposure to any direct acting agents.
  • Have a diagnosis of HCV.

This is a partial list of eligibility requirements.

Study Details

Clinical Trial Investigator

Lisa Boggio, MD

Contact Information

Lisa Boggio, MD

(312) 942-3034


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more